{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-011226","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2021-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.432545+00:00","generated_at":"2026-06-29T15:21:53.679301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MeiraGTx Q2 net loss $20.1M ($0.46/sh); cash runway into Q2 2023","bullets":["Net loss attributable to shareholders $20.1M ($0.46/sh) vs $25.4M ($0.69/sh) in Q2 2020.","License revenue $5.1M (up from $2.5M); R&D spend $15.2M, G&A $10.4M.","Cash and equivalents $172.6M (down from $194.8M); believes funded into Q2 2023.","Expects to initiate Phase 3 Lumeos trial for XLRP, Phase 3 for AAV-RPE65, and file IND for AAV-GAD in Parkinsons in H2 2021.","Manufacturing facility to support at least six clinical programs in next 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-011226","json":"https://secwatch.observer/filing/0001558370-21-011226.json","markdown":"https://secwatch.observer/filing/0001558370-21-011226.md","text":"https://secwatch.observer/filing/0001558370-21-011226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837021011226/0001558370-21-011226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837021011226/mgtx-20210811x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T15:21:53.679301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}